Relation between interleukin-6 and homocysteine in type 2 diabetes mellitus

2000 ◽  
Vol 50 ◽  
pp. 130
Author(s):  
Olga Kolcowa ◽  
Elzbieta Orłowska-Kunikowska ◽  
Krzystof Narkiewicz ◽  
Anna Owczarzak ◽  
Wiesława Łysiak-Szydłowska
Keyword(s):  
Diabetes Mellitus ◽  
Type 2 Diabetes ◽  
Type 2 Diabetes Mellitus ◽  
Interleukin 6

Increased Serum WISP1 Levels are Associated with Lower Extremity Atherosclerotic Disease in Patients with type 2 Diabetes Mellitus

2021 ◽  
Author(s):  
Yangyang Cheng ◽  
Xiaohui Du ◽  
Bilin Zhang ◽  
Junxia Zhang
Keyword(s):  
Diabetes Mellitus ◽  
Type 2 Diabetes ◽  
Type 2 Diabetes Mellitus ◽  
Lower Extremity ◽  
Interleukin 6 ◽  
Atherosclerotic Disease ◽  
Enzyme Linked Immunosorbent Assay ◽  
Diabetic Patients ◽  
Newly Diagnosed

Abstract Background Serum wnt1-induced signaling pathway protein 1 (WISP1) levels are increased with obesity, which is a common complication associated with lower extremity atherosclerotic disease (LEAD). However, to date, the relationship between elevated WISP1 levels and the incidence of lower extremity atherosclerotic disease (LEAD) in type 2 diabetes mellitus (T2DM) remains unclear. Methods 174 newly diagnosed type 2 diabetic patients were enrolled in our study. Patients were divided into two groups, LEAD group (n=100) and control group (n=74). Anthropometric parameters, blood pressure and some biochemical parameters were obtained. Body composition was detected by bioelectrical impedance analysis (BIA). Levels of serum insulin were determined by radioimmunoassay. Serum WISP1 and interleukin 6 (IL-6) levels were determined using an enzyme-linked immunosorbent assay. Results It was shown that serum WISP1 levels in diabetic patients with LEAD were higher than those without LEAD (P<0.001). Serum WISP1 levels were positively related with waist circumference (r=0.237, P=0.003), waist-hip ratio (r=0.22, P=0.006), visceral fat area (r=0.354, P<0.001), serum creatinine (r=0.192, P=0.012), interleukin 6 (r=0.182, P=0.032), c-reactive protein (r=0.681, P<0.001), triglycerides (r=0.119, P<0.001), fasting glucose (r=0.196, P=0.011), glycated hemoglobin (r=0.284, P<0.001), and HOMA-IR (r=0.285, P<0.026). Compared with the lowest tertile, the odds ratio of the middle tertile for LEAD incidence was 3.27 (95% CI, 1.24–8.64) and 4.46 (95% CI, 1.62–12.29) for the highest tertile after adjusting confounding factors. Conclusion The results suggest that increased serum WISP1 levels independently contribute to the incidence of LEAD in patients with newly diagnosed T2DM.

Acute hyperinsulinemia raises plasma interleukin-6 in both nondiabetic and type 2 diabetes mellitus subjects, and this effect is inversely associated with body mass index

Metabolism ◽  
2009 ◽  
Vol 58 (6) ◽  
pp. 860-866 ◽  
Author(s):  
Toralph Ruge ◽  
J. Andrew Lockton ◽  
Frida Renstrom ◽  
Theodore Lystig ◽  
Valentina Sukonina ◽  
...  
Keyword(s):  
Diabetes Mellitus ◽  
Type 2 Diabetes ◽  
Body Mass Index ◽  
Type 2 Diabetes Mellitus ◽  
Body Mass ◽  
Interleukin 6

The association of the 174G>C polymorphism of interleukin 6 gene with diabetic nephropathy in patients with type 2 diabetes mellitus

2013 ◽  
Vol 27 (6) ◽  
pp. 576-579 ◽  
Author(s):  
Stavroula Papaoikonomou ◽  
Nicholas Tentolouris ◽  
Dimitris Tousoulis ◽  
Dimitris Papadodiannis ◽  
Antigoni Miliou ◽  
...  
Keyword(s):  
Diabetes Mellitus ◽  
Type 2 Diabetes ◽  
Type 2 Diabetes Mellitus ◽  
Diabetic Nephropathy ◽  
Interleukin 6

scholarly journals Genetic Relationship Between Interleukın-6 rs1800796 Variants,  Interleukın-6 Plasma Levels and Susceptibility to Type 2 Diabetes Mellitus and Diabetic Nephropathy

2021 ◽  
Author(s):  
Nezaket COBAN ◽  
Aysegul Bayramoglu ◽  
Zeynep TEMIZ
Keyword(s):  
Diabetes Mellitus ◽  
Type 2 Diabetes ◽  
Type 2 Diabetes Mellitus ◽  
Diabetic Nephropathy ◽  
Inflammatory Cytokines ◽  
Interleukin 6 ◽  
Enzyme Linked Immunosorbent Assay ◽  
Control Group ◽  
Significant Difference

Abstract Type 2 diabetes mellitus (T2DM) is very common worldwide and genetically heterogeneous. One of the microvascular complications is diabetic nephropathy (DN). In recent years, T2DM has been described as a disease caused by chronic inflammation. The imbalance between pro- and anti-inflammatory cytokines causes inflammation. One of the candidate genes associated with T2DM and DN is the Interleukin-6 (IL-6) gene, one of the pro-inflammatory cytokines. This study was conducted to determine the polymorphism frequencies of the IL-6 gene rs1800796 and investigate the role of this polymorphism in the development of T2DM and DN. Genomic DNA that was obtained from 261 people was used in the study. IL-6 gene rs1800796 polymorphism was determined using the PCR, restriction fragment length polymorphism (RFLP) and electrophoresis. IL-6 gene PCR products were discontinued by treatment with restriction enzyme BsrBI and were analyzed in 2% agarose gel electrophoresis. IL-6 (Bioassay technology laboratory, Shangai, China) level was examined by enzyme-linked immunosorbent assay (ELISA) using a commercial kit. The results were statistically analyzed. The frequencies of rs1800796 genotypes were found to be GG 70.7%, GC 28.5%, CC 0.8% in the control group and GG 87.8%, GC 9.9 %, CC 2.3% in T2DM patients. Although there was a statistically significant difference between the control group and the T2DM patient group in genotype and allele frequencies, there was no significant difference in DN. The G allele frequency was also significantly higher in the T2DM group (p=0.000). IL-6 levels were determinated increased in patients with Type-2 diabetes compared to the control group. However; there was no significant statistically. We can say that IL-6 rs1800796 polymorphism is related to T2DM and G allele can be used as a useful genetic marker; this polymorphism is not related to DN, though.

scholarly journals INTERLEUKIN LEVELS IN PATIENTS WITH ESSENTIAL HYPERTENSION COMBINED WITH TYPE 2 DIABETES MELLITUS

2019 ◽  
Vol 6 (1) ◽  
pp. 38-42
Author(s):  
B.O. Shelest
Keyword(s):  
Diabetes Mellitus ◽  
Type 2 Diabetes ◽  
Type 2 Diabetes Mellitus ◽  
Essential Hypertension ◽  
Interleukin 6 ◽  
Inflammatory Marker ◽  
Cardiovascular Complications ◽  
The Relationship ◽  
Diabetes And Obesity

INTERLEUKIN LEVELS IN PATIENTS WITH ESSENTIAL HYPERTENSION COMBINED WITH TYPE 2 DIABETES MELLITUSShelest B.O.The problem of combined course of hypertension of diabetes mellitus type 2 and obesity is becoming more common. This variant of comorbidity crucially increases the risk of cardiovascular complications. Inflammation is considered as an important link between the progression of hypertension and the development of adverse events. This study is devoted to the question of the relationship between the pro-inflammatory marker interleukin-6 and the increased blood pressure in patients with concomitant diabetes and obesity. The treatment of such patients with combined pathology remains the actual and difficult issue of medical practice. The article analyses the dynamics of interleukin-6 in the process of treatment with a fixed triple antihypertensive combination. Key words: hypertension, interleukin-6, type 2 diabetes mellitus, obesity. РІВНІ ІНТЕРЛЕЙКІНІВ У ХВОРИХ НА ГІПЕРТОНІЧНУ ХВОРОБУ У ПОЄДНАННІ З ЦУКРОВИМ ДІАБЕТОМ 2 ТИПУ Шелест Б.О.Все більшого поширення набуває проблема поєднаного перебігу гіпертензії цукрового діабету 2 типу та ожиріння. Такий варіант коморбидности різко підвищує ризик кардіоваскулярних ускладнень. Важливою ланкою в прогресуванні гіпертензії і розвитку несприятливих подій відводиться запаленню. Дана робота присвячена питанню залежності прозапального маркера інтерлейкіну-6 і підвищених цифр артеріального тиску у хворих з супутнім цукровим діабетом 2 типу і ожирінням. Актуальним і складним питанням медичної практики залишається лікування таких пацієнтів з поєднаною патологією. У статті аналізується динаміка інтерлейкіну-6 в процесі лікування потрійною фіксованою антигіпертензивною комбінацією.Ключові слова: гіпертонічна хвороба, інтерлейкін-6, цукровий діабет 2 типу, ожиріння. УРОВЕНЬ ИНТЕРЛЕЙКИНОВ У ПАЦИЕНТОВ С ГИПЕРТОНИЧЕСКОЙ БОЛЕЗНЬЮ В СОЧЕТАНИИ С САХАРНЫМ ДИАБЕТОМ 2 ТИПА. Шелест Б.А.Все большее распространение приобретает проблема сочетанного течения гипертензии сахарного диабета 2 типа и ожирения. Такой вариант коморбидности резко повышает риск кардиоваскулярных осложнений. Важным звеном в прогрессировании гипертензии и развитии неблагоприятных событий отводится воспалению. Даннаяработапосвящена вопросу зависимости провоспалительного маркера интерлейкина-6 и наличием повышенных цифр артериального давления у больных с сопутствующим сахарным диабетом и ожирением. Актуальным и сложным вопросом медицинской практики остается лечение таких пациентов с сочетанной патологией. В статье анализируется динамика интерлейкина-6 в процессе лечения фиксированной тройной антигипертензивной комбинацией. Ключевые слова: гипертоническая болезнь, интерлейкин-6, сахарный диабет 2 типа, ожирение.

Role of Interleukin-6 in Development of Insulin Resistance and Type 2 Diabetes Mellitus

2017 ◽  
Vol 27 (3) ◽  
pp. 229-236 ◽  
Author(s):  
Kanwal Rehman ◽  
Muhammad Sajid Hamid Akash ◽  
Aamira Liaqat ◽  
Shagufta Kamal ◽  
Muhammad Imran Qadir ◽  
...  
Keyword(s):  
Diabetes Mellitus ◽  
Insulin Resistance ◽  
Type 2 Diabetes ◽  
Type 2 Diabetes Mellitus ◽  
Interleukin 6

scholarly journals Bariatric surgery as a model to explore the basis and consequences of the Reaven hypothesis: Small, dense low-density lipoprotein and interleukin-6

2019 ◽  
Vol 16 (2) ◽  
pp. 144-152 ◽  
Author(s):  
Safwaan Adam ◽  
Yifen Liu ◽  
Tarza Siahmansur ◽  
Jan H Ho ◽  
Shaishav S Dhage ◽  
...  
Keyword(s):  
Diabetes Mellitus ◽  
Insulin Resistance ◽  
Type 2 Diabetes ◽  
Bariatric Surgery ◽  
Type 2 Diabetes Mellitus ◽  
Interleukin 6 ◽  
Low Density Lipoprotein ◽  
Density Lipoprotein ◽  
Low Density

Background: Reaven originally described the clustering of insulin resistance/hyperinsulinaemia, obesity (particularly visceral), altered cytokine levels, glucose intolerance, hypertriglyceridaemia and low high-density lipoprotein cholesterol. Subsequently, a potentially highly atherogenic small, dense low-density lipoprotein was also reported. We have studied the effect of bariatric surgery on this and other risk factors for atherosclerosis. Methods: Forty patients (20 with type 2 diabetes mellitus) undergoing bariatric surgery were studied before and 1 year after bariatric surgery. Results: Twelve months after bariatric surgery, median body mass index had decreased from 49.5 to 36.5 kg/m2, fasting insulin from 21.3 to 7.8 mU/L and insulin resistance (homeostatic model assessment of insulin resistance) from 5.9 to 1.8 (all p < 0.001). Thirteen out of 20 patients had remission from type 2 diabetes mellitus. Highly sensitive C-reactive protein, interleukin-6, fasting triglycerides ( p < 0.001) and small, dense low-density lipoprotein ( p < 0.001) decreased, while high-density lipoprotein cholesterol increased ( p < 0.001) significantly, irrespective of having type 2 diabetes mellitus and/or being treated with statin therapy before surgery. Conclusion: The association between marked weight loss and change in insulin resistance and hyperinsulinaemia with the change in small, dense low-density lipoprotein and interleukin-6 warrants further investigation. Bariatric surgery provides a model for investigating the mechanisms linking insulin resistance/hyperinsulinaemia to atherosclerosis.

Sign in / Sign up

Export Citation Format

Share Document